Last updated August 1, 2026, 10:30 AM ET · All times are Eastern Time.
MAReleased
Mastercard
July 30, 2026 · Second Quarter 2026
Actual results
- Adjusted EPS: $5.04; revenue: $9.3B, up 14% YoY
- Cross-border volume rose 12%; switched transactions rose 9%
- Adjusted operating margin reached 61.1%, up 1.2 percentage points
Broad-based payment, cross-border and services growth points to resilient demand. Watch whether incentive growth can remain compatible with premium margins.
REGNReleased
Regeneron Pharmaceuticals
July 30, 2026 · Second Quarter 2026
Actual results
- Non-GAAP EPS: $14.29; revenue: $4.291B, up 17% YoY
- Dupixent global sales rose 38% to $6.0B
- U.S. EYLEA HD sales rose 52%; global Libtayo sales rose 30%
Several major products reached records at the same time, reducing single-product dependence. EYLEA competition and pipeline conversion remain the main follow-through questions.
YUMReleased
Yum! Brands
July 30, 2026 · Second Quarter 2026
Actual results
- EPS excluding special items: $1.62; revenue: $2.169B
- Worldwide system sales rose 5% excluding currency
- Taco Bell same-store sales rose 7%; KFC rose 2%; Pizza Hut fell 1%
Taco Bell strength contrasted with Pizza Hut weakness. The disposal can sharpen focus, but execution and post-separation growth quality still matter.
AAPLReleased
Apple
July 30, 2026 · Fiscal Third Quarter 2026
Actual results
- EPS: $2.02 vs. $1.89 FactSet consensus
- Revenue: $109.417B vs. $109.0B consensus
- iPhone revenue rose 21.7%; Greater China revenue rose 22.4%
Hardware demand was strong, but the market discounted the one-time margin benefit and demanded more evidence on durable Services growth and AI-driven upside.
AMZNReleased
Amazon
July 30, 2026 · Second Quarter 2026
Actual results
- EPS: $5.75; revenue: $200.606B vs. $196.4B S&P Capital IQ consensus
- AWS revenue rose 37% to $42.232B; AWS operating margin reached 39.4%
- Q3 revenue guidance: $197B–$202B; operating income: $22.5B–$26.5B
AWS acceleration and margin expansion gave investors evidence that heavy AI spending is producing returns, though negative trailing free cash flow remains a real risk.
XOMReleased
Exxon Mobil
July 31, 2026 · Second Quarter 2026
Actual results
- Adjusted EPS: $3.52; GAAP earnings: $14.5B
- Operating cash flow: $23.6B; free cash flow: $17.2B
- Upstream production was the highest in more than two decades, excluding Middle East disruptions
Volume, cost savings and cash flow supported the quarter beyond oil prices. The next test is how much of that improvement persists if commodity prices normalize.
CVXReleased
Chevron
July 31, 2026 · Second Quarter 2026
Actual results
- Adjusted EPS: $6.06; sales and other operating revenue: $67.199B
- Adjusted earnings: $12.0B
- Worldwide production rose 20% YoY; U.S. production and refinery crude throughput set records
Production and refinery utilization made the quarter more than a simple oil-price story, but cycle exposure and project execution remain central to valuation.
ABBVReleased
AbbVie
July 31, 2026 · Second Quarter 2026
Actual results
- Adjusted EPS: $3.65; revenue: $16.990B, up 10.2% YoY
- Skyrizi and Rinvoq each grew about 24%
- Neuroscience revenue rose 20.3%, continuing to offset Humira erosion
Skyrizi, Rinvoq and neuroscience continue to improve the mix. The small guidance reduction reflects proposed-deal dilution more than an abrupt weakening in the core business.
MRNAReleased
Moderna
July 31, 2026 · Second Quarter 2026
Actual results
- GAAP loss per share: $1.97; revenue: $145M, up 2% YoY
- R&D expense fell 7%; SG&A fell 6%
- Quarter-end cash, cash equivalents and investments: $6.9B
Expense discipline improved, but commercial scale remains limited and cash use remains high. The mFLUSIVA decision and pivotal readouts are the next major catalysts and risks.